Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Migraine Disorders: HELP
Articles from Minnesota
Based on 90 articles published since 2008

These are the 90 published articles about Migraine Disorders that originated from Minnesota during 2008-2019.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4
1 Editorial Effectiveness in acute migraine treatment: how it might matter. 2015

Mack, Kenneth J / Digre, Kathleen. ·From the Mayo Clinic (K.J.M.), Rochester, MN · and University of Utah (K.D.), Salt Lake City. ·Neurology · Pubmed #25609759.

ABSTRACT: -- No abstract --

2 Editorial Recent studies on PFO and migraine: is there a future for closure? 2008

Taylor, Frederick R / Tepper, Stewart J / Stillman, Mark J. ·Park Nicollet Headache Clinic, Minneapolis, MN, USA. ·Headache · Pubmed #18687080.

ABSTRACT: -- No abstract --

3 Review Clinical pearls in neurology 2018. 2018

Singh, Rashmi B Halker / Litin, Scott C / Bundrick, John B. ·Department of Neurology, Mayo Clinic, Scottsdale, AZ, United States. · Division of General Internal Medicine, Mayo Clinic, Rochester, MN, United States. · Division of General Internal Medicine, Mayo Clinic, Rochester, MN, United States. Electronic address: bundrick.john@mayo.edu. ·Dis Mon · Pubmed #29880265.

ABSTRACT: -- No abstract --

4 Review Migraine Throughout the Female Reproductive Life Cycle. 2018

Faubion, Stephanie S / Batur, Pelin / Calhoun, Anne H. ·Women's Health Clinic, Division of General Internal Medicine, Mayo Clinic, Rochester, MN. Electronic address: faubion.stephanie@mayo.edu. · Department of Internal Medicine, Primary Care Women's Health, Cleveland Clinic, Cleveland, OH. · Carolina Headache Institute, Durham, NC; Department of Anesthesiology and Department of Psychiatry, University of North Carolina, Chapel Hill, NC. ·Mayo Clin Proc · Pubmed #29728203.

ABSTRACT: By the end of their reproductive life cycle, roughly 40% of women have experienced migraine. Women have certain times of vulnerability for migraine that relate to abrupt declines in estrogen levels. Specifically, the prevalence of migraine is higher after menarche, during menstruation, during the postpartum period, and during perimenopause, but it is commonly lower during the second and third trimesters of pregnancy and the postmenopausal years. Therapeutic strategies for migraine management include hormonal manipulation aimed at eliminating or minimizing the decreases in estrogen that trigger the especially severe menstrual-related attacks. This article reviews special considerations for triptan use in pregnant and lactating women and in women with high risk for cardiovascular disease. Health care professionals caring for women throughout their life span should be aware of these important sex-based differences in migraine and migraine management.

5 Review Aura and Other Neurologic Dysfunction in or with Migraine. 2017

Kissoon, Narayan R / Cutrer, Fred Michael. ·Division of Headache, Department of Neurology, Mayo Clinic, Rochester, MN, USA . ·Headache · Pubmed #28542895.

ABSTRACT: PREMISE: Migraine can present with a wide range of neurological symptoms. PROBLEM: Based on currently available data, the symptoms of typical migraine aura are most likely related to cortical spreading depression (CSD), and evidence supports that CSD can lead to trigeminovascular activation resulting in the headache phase of migraine. POTENTIAL SOLUTION: An alternative diagnosis to migraine aura should be considered if migrainous headaches present with transient neurological symptoms that have features inconsistent with aura.

6 Review Complementary and integrative medicine in the management of headache. 2017

Millstine, Denise / Chen, Christina Y / Bauer, Brent. ·Integrative Medicine Section, Department of General Internal Medicine; Women's Health Internal Medicine, Mayo Clinic, Scottsdale, AZ 85260, USA Millstine.Denise@mayo.edu. · Primary Care Internal Medicine, Division of Geriatrics, Mayo Clinic, Rochester, MN 55905 USA. · Integrative Medicine Program, Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA. ·BMJ · Pubmed #28512119.

ABSTRACT: Headaches, including primary headaches such as migraine and tension-type headache, are a common clinical problem. Complementary and integrative medicine (CIM), formerly known as complementary and alternative medicine (CAM), uses evidence informed modalities to assist in the health and healing of patients. CIM commonly includes the use of nutrition, movement practices, manual therapy, traditional Chinese medicine, and mind-body strategies. This review summarizes the literature on the use of CIM for primary headache and is based on five meta-analyses, seven systematic reviews, and 34 randomized controlled trials (RCTs). The overall quality of the evidence for CIM in headache management is generally low and occasionally moderate. Available evidence suggests that traditional Chinese medicine including acupuncture, massage, yoga, biofeedback, and meditation have a positive effect on migraine and tension headaches. Spinal manipulation, chiropractic care, some supplements and botanicals, diet alteration, and hydrotherapy may also be beneficial in migraine headache. CIM has not been studied or it is not effective for cluster headache. Further research is needed to determine the most effective role for CIM in patients with headache.

7 Review Oxytocin and Migraine Headache. 2017

Tzabazis, Alexander / Kori, Shashi / Mechanic, Jordan / Miller, James / Pascual, Conrado / Manering, Neil / Carson, Dean / Klukinov, Michael / Spierings, Egilius / Jacobs, Daniel / Cuellar, Jason / Frey, William H / Hanson, Leah / Angst, Martin / Yeomans, David C. ·Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, CA. · Trigemina, Inc., Moraga, CA. · Department of Neurology, Tufts University School of Dental Medicine, Boston, MA. · Department of Plastic Surgery, Kaiser Permanente Medical Center, San Jose, CA. · HealthPartners Center for Memory and Aging, Regions Hospital, St. Paul, MN, USA. ·Headache · Pubmed #28485846.

ABSTRACT: This article reviews material presented at the 2016 Scottsdale Headache Symposium. This presentation provided scientific results and rationale for the use of intranasal oxytocin for the treatment of migraine headache. Results from preclinical experiments are reviewed, including in vitro experiments demonstrating that trigeminal ganglia neurons possess oxytocin receptors and are inhibited by oxytocin. Furthermore, most of these same neurons contain CGRP, the release of which is inhibited by oxytocin. Results are also presented which demonstrate that nasal oxytocin inhibits responses of trigeminal nucleus caudalis neurons to noxious stimulation using either noxious facial shock or nitroglycerin infusion. These studies led to testing the analgesic effect of intranasal oxytocin in episodic migraineurs-studies which did not meet their primary endpoint of pain relief at 2 h, but which were highly informative and led to additional rat studies wherein inflammation was found to dramatically upregulate the number of oxytocin receptors available on trigeminal neurons. This importance of inflammation was supported by a series of in vivo rat behavioral studies, which demonstrated a clear craniofacial analgesic effect when a pre-existing inflammatory injury was present. The significance of inflammation was further solidified by a small single-dose clinical study, which showed analgesic efficacy that was substantially stronger in chronic migraine patients that had not taken an anti-inflammatory drug within 24 h of oxytocin dosing. A follow-on open label study examining effects of one month of intranasal oxytocin dosing did show a reduction in pain, but a more impressive decrease in the frequency of headaches in both chronic and high frequency episodic migraineurs. This study led to a multicountry double blind, placebo controlled study studying whether, over 2 months of dosing, "as needed" dosing of intranasal oxytocin by chronic and high frequency migraineurs would reduce the frequency of their headaches compared to a 1-month baseline period. This study failed to meet its primary endpoint, due to an extraordinarily high placebo rate in the country of most of the patients (Chile), but was also highly informative, showing strong results in other countries and strong post hoc indications of efficacy. The results provide a strong argument for further development of intranasal oxytocin for migraine prophylaxis.

8 Review No Laughing Matter: Gelastic Migraine and Other Unusual Headache Syndromes. 2016

Mathew, Paul G / Robertson, Carrie E. ·John R. Graham Headache Center, Department of Neurology, Brigham and Women's Hospital, 1153 Centre Street, Suite 4970, Boston, MA, 02130, USA. PMATHEW@partners.org. · Department of Neurology, Harvard Vanguard Medical Associates, Braintree, MA, USA. PMATHEW@partners.org. · Division of Neurology, Cambridge Health Alliance, Cambridge, MA, USA. PMATHEW@partners.org. · Harvard Medical School, Boston, MA, USA. PMATHEW@partners.org. · Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA. ·Curr Pain Headache Rep · Pubmed #27038971.

ABSTRACT: Primary and secondary headache disorders have established diagnostic criteria in the International Classification of Headache Disorders IIIb, as well as classic findings, which although not part of the formal criteria are often suggestive of a particular diagnosis. At times, headache disorders can involve unusual symptoms that lack an identifiable secondary cause. This review will discuss some of these unusual symptoms, including headache associated auditory and olfactory symptoms, as well as two case reports involving gelastic migraine and migrainous thoracalgia.

9 Review Psychogenic Non-epileptic Seizures: An Updated Primer. 2016

Baslet, Gaston / Seshadri, Ashok / Bermeo-Ovalle, Adriana / Willment, Kim / Myers, Lorna. ·Department of Psychiatry, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA. Electronic address: gbaslet@partners.org. · Department of Psychiatry, Mayo Clinic, Rochester, MN. · Department of Neurology, Rush University Medical Center, Chicago, IL. · Harvard Medical School, Boston, MA; Department of Neurology, Brigham and Women's Hospital, Boston, MA. · Northeast Regional Epilepsy Group, New York, NY. ·Psychosomatics · Pubmed #26791511.

ABSTRACT: BACKGROUND: Psychogenic non-epileptic seizures are the most common paroxysmal event misdiagnosed as epilepsy. They significantly affect quality of life, functional status, and use of medical resources. OBJECTIVE: The goal of this review is to provide guidance to psychiatrists and other mental health professionals in the understanding and practical management of this condition. RESULTS: An abundance of new reports on the pathogenesis and effective treatments have become available over the last decade, yet specific barriers impede the fluid transition to treatment and remain an important challenge in the management of patients with psychogenic non-epileptic seizures. In the context of these difficulties, we initially present background information on psychogenic non-epileptic seizures covering their historic context, epidemiology, etiologic factors (including psychiatric, neuromedical, and neuropsychological factors), and current neurobiological models. Updated evidence-based treatments are discussed along with data on long-term outcomes. We also provide practical tools to help clinicians navigate differential diagnoses, establish their interdisciplinary roles, communicate the diagnosis, deliver treatment, and sort out commonly encountered challenges in the management of this condition.

10 Review Mast Cell-Mediated Mechanisms of Nociception. 2015

Aich, Anupam / Afrin, Lawrence B / Gupta, Kalpna. ·Vascular Biology Center, Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA. aaich@umn.edu. · Vascular Biology Center, Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA. afrinl@umn.edu. · Vascular Biology Center, Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA. gupta014@umn.edu. ·Int J Mol Sci · Pubmed #26690128.

ABSTRACT: Mast cells are tissue-resident immune cells that release immuno-modulators, chemo-attractants, vasoactive compounds, neuropeptides and growth factors in response to allergens and pathogens constituting a first line of host defense. The neuroimmune interface of immune cells modulating synaptic responses has been of increasing interest, and mast cells have been proposed as key players in orchestrating inflammation-associated pain pathobiology due to their proximity to both vasculature and nerve fibers. Molecular underpinnings of mast cell-mediated pain can be disease-specific. Understanding such mechanisms is critical for developing disease-specific targeted therapeutics to improve analgesic outcomes. We review molecular mechanisms that may contribute to nociception in a disease-specific manner.

11 Review Retrospective review and telephone follow-up to evaluate a physical therapy protocol for treating persistent postural-perceptual dizziness: A pilot study. 2015

Thompson, Karla J / Goetting, Jay C / Staab, Jeffrey P / Shepard, Neil T. ·Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, MN, USA. · Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA. · Department of Otorhinolaryngology, Mayo Clinic, Rochester, MN, USA. ·J Vestib Res · Pubmed #26410674.

ABSTRACT: BACKGROUND: Persistent postural-perceptual dizziness (PPPD) (formerly chronic subjective dizziness) may be treated using the habituation form of vestibular and balance rehabilitation therapy (VBRT), but therapeutic outcomes have not been formally investigated. OBJECTIVE: This pilot study gathered the first data on the efficacy of VBRT for individuals with well-characterized PPPD alone or PPPD plus neurotologic comorbidities (vestibular migraine or compensated vestibular deficits). METHODS: Twenty-six participants were surveyed by telephone an average of 27.5 months after receiving education about PPPD and instructions for home-based VBRT programs. Participants were queried about exercise compliance, perceived benefits of therapy, degree of visual or motion sensitivity remaining, disability level, and other interventions. RESULTS: Twenty-two of 26 participants found physical therapy consultation helpful. Fourteen found VBRT exercises beneficial, including 8 of 12 who had PPPD alone and 6 of 14 who had PPPD with co-morbidities. Of the 14 participants who found VBRT helpful, 7 obtained relief of sensitivity to head/body motion, 5 relief of sensitivity to visual stimuli, and 4 complete remission. Comparable numbers for the 12 participants who found VBRT not helpful were 1 (head/body motion), 3 (visual stimuli), and 0 (remission). CONCLUSIONS: This pilot study offers the first data supporting the habituation form of VBRT for treatment of PPPD.

12 Review Overview of the International Classification of Vestibular Disorders. 2015

Bisdorff, Alexandre R / Staab, Jeffrey P / Newman-Toker, David E. ·Department of Neurology, Centre Hospitalier Emile Mayrisch, rue Emile Mayrisch, Esch-sur-Alzette 4005, Luxembourg. Electronic address: alexbis@pt.lu. · Department of Psychiatry and Psychology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA. · Departments of Neurology, Otolaryngology, and Epidemiology, The Johns Hopkins University School of Medicine & Bloomberg School of Public Health, The Johns Hopkins Hospital, CRB-II, Room 2M-03 North, 1550 Orleans Street, Baltimore, MD 21231, USA. ·Neurol Clin · Pubmed #26231270.

ABSTRACT: Classifications and definitions are essential to facilitate communication; promote accurate diagnostic criteria; develop, test, and use effective therapies; and specify knowledge gaps. This article describes the development of the International Classification of Vestibular Disorders (ICVD) initiative. It describes its history, scope, and goals. The Bárány Society has played a central role in organizing the ICVD by establishing internal development processes and outreach to other scientific societies. The ICVD is organized in four layers. The current focus is on disorders with a high epidemiologic importance, such as Menière disease, benign paroxysmal positional vertigo, vestibular migraine, and behavioral aspects of vestibular disorders.

13 Review Tobacco, Nicotine, and Headache. 2015

Taylor, Frederick R. ·Department of Neurology, University of Minnesota School of Medicine, Minneapolis, MN, USA. ·Headache · Pubmed #26140522.

ABSTRACT: BACKGROUND: Migraineurs variably attribute the cause of their headache to tobacco exposure, whereas tobacco is often stated to cause headache-related disability worldwide. Given tobacco's physiological and emotional addictiveness and migraine's substantial economic impact, improved functionality can be difficult for those with migraine exposed to tobacco products. Environmental tobacco exposure in indoor spaces and workplaces is associated with exacerbation of headache. Avoidance of headache triggers is included in most comprehensive migraine treatment programs, yet tobacco awareness, avoidance, or coping is rarely emphasized as part of that regimen. OBJECTIVE: The aims of this study were to examine the various types of tobacco products to which headache sufferers are exposed and the known basic mechanisms by which tobacco (nicotine) exposure promotes headache pain, and to review the extensive literature on tobacco related to headache with a detailed descriptive narrative providing the basis for conclusions regarding association of noncluster headache-related tobacco exposure. Tobacco-related recommendations are offered. METHODS: MEDLINE, EMBASE, and Google Scholar databases were searched without yearly restriction through the date of submission (May 2015), using the MeSH terms "tobacco," "tobacco products," "smoking," "tobacco use," "headache," and "headache disorders." The selection of articles was not limited to English studies or to humans. Articles were excluded when "headache" and "tobacco" were not both mentioned with data provided. Case series were included. Bibliographies of all articles were screened for additional relevant articles. RESULTS: Although migraineurs worldwide report tobacco smoke among triggers, it is rarely among the highest in frequency, and biases abound with predominantly noncontrolled retrospective data. Prospective population-based diary data are extremely limited, and no controlled trials exist to confirm a cause and effect for headache of any type. Although some studies are nonsupportive and even conflicting, headache, pain, and tobacco exposure currently remain associated. CONCLUSION: Conflicting data support the validity of patient-reported environmental tobacco exposure as a headache trigger. Prospective controlled studies are needed, but unlikely to be performed, to determine the extent that tobacco influences the headache process, in addition to other under-recognized factors. Meanwhile, because of numerous other negative health effects, decreased tobacco exposure should be recommended to headache patients of all ages in hopes of decreasing disability and improving functionality.

14 Review Comorbidities in vestibular migraine. 2014

Eggers, Scott D Z / Neff, Brian A / Shepard, Neil T / Staab, Jeffrey P. ·Department of Neurology, Mayo Clinic, Rochester, MN, USA. · Department of Otorhinolaryngology, Mayo Clinic, Rochester, MN, USA. · Division of Audiology, Mayo Clinic, Rochester, MN, USA. · Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA. ·J Vestib Res · Pubmed #25564081.

ABSTRACT: A growing body of clinical and epidemiological evidence supports a specific relationship between vestibular symptoms and migraine. Without a biomarker or complete understanding of pathophysiology, diagnosis of vestibular migraine (VM) currently depends upon symptoms in two dimensions: episodic vestibular symptoms temporally related to migraine symptoms. The Bárány Society and the International Headache Society have recently developed consensus diagnostic criteria. However, many issues remain unsettled, including the type, duration, and timing of vestibular symptoms related to headache that should be required for diagnosing VM. This paper focuses on the challenging third dimension of comorbidity, a frequent cause of diagnostic uncertainty that may confound clinical application and research validation of VM criteria. Several other neurotologic conditions occur more frequently in migraineurs than controls, including benign paroxysmal positional vertigo, Ménière's disease, and motion sickness. Patients with VM also have high rates of chronic subjective dizziness, which may be associated with anxious, introverted temperaments that can affect clinical presentation and treatment response. Broadly inclusive studies of well-characterized patients with other neurotologic and psychiatric comorbidities are needed to fully understand how vestibular symptoms and migraine interact in order to truly validate vestibular migraine, distill its essential features, define its boundaries, and characterize overlapping comorbidities.

15 Review Our evolving understanding of migraine with aura. 2014

DeLange, Justin M / Cutrer, F Michael. ·Mayo Clinic, 200 W First Street, Rochester, MN, 55905, USA. ·Curr Pain Headache Rep · Pubmed #25230799.

ABSTRACT: Migraine aura consists of fully reversible focal neurologic symptoms that may precede or coexist with headache in a significant minority of migraine patients. Typical aura symptoms include visual, sensory, and language disturbances. The most recent International Classification of Headache Disorders, 3rd edition (beta version) has added other aura types such as brainstem localizing symptoms, lateralizing weakness, and monocular visual loss. Currently available data from animal models and functional neuroimaging in humans implicate cortical spreading depression (CSD) as the phenomenon underlying migraine aura. Ongoing study suggests that susceptibility to migraine aura and CSD may be genetically mediated. CSD appears to be a potential target for future development of migraine-specific preventive therapies.

16 Review PFO closure: rational, procedure and devices. 2014

Reiter, R / Bertog, S G / Vaskelyte, L / Franke, J / Lam, S / Gafoor, S / Hofmann, I / Hornung, M / Sievert, H. ·The University of Minnesota Medical School Minneapolis, MN, USA - horstsievertmd@aol.com. ·Minerva Cardioangiol · Pubmed #24500219.

ABSTRACT: Patent foramen ovale (PFO) is a common anatomical variant occurring in 20-25% of the population. In most cases, a PFO remains asymptomatic. However it allows for any venous particle such as thrombus, air or vasoactive substances to bypass the lung and enter the arterial circulation. Accordingly, PFO's have been linked to cryptogenic stroke, migraine and decompression illness. While the number of device closures have been increasing the therapy remains controversial as ‑ until recently ‑ data supporting PFO closure came from non randomized studies only. In this review we will discuss the existing data on PFO closure including results of the three randomized controlled trials comparing device closure with medical therapy in patients with cryptogenic stroke. We will also focus on the implantation technique, the complications and the different devices that are used for this procedure.

17 Review Episodic migraines in children: limited evidence on preventive pharmacological treatments. 2013

Shamliyan, Tatyana A / Kane, Robert L / Ramakrishnan, Rema / Taylor, Frederick R. ·1Division of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis, MN, USA. ·J Child Neurol · Pubmed #23752070.

ABSTRACT: The authors conducted a systematic literature review of preventive pharmacological treatments for episodic childhood migraines searching several databases through May 20, 2012. Episodic migraine prevention was examined in 24 publications of randomized controlled trials that enrolled 1578 children in 16 nonrandomized studies. Single randomized controlled trials provided low-strength evidence that propranolol would result in complete cessation of migraine attacks in 713 per 1000 children treated (95% confidence interval, 452-974); trazodone and nimodipine decreased migraine days, while topiramate, divalproex, and clonidine were no more effective than placebo in preventing migraines. Migraine prevention with multidisciplinary drug management was not sustained at 6 months. Divalproex resulted in treatment discontinuation due to adverse effects, and topiramate increased the risk of paresthesia, upper respiratory tract infection, and weight loss. Long-term preventive benefits and improvement in disability and quality of life are unknown. No studies examined quality of life or provided evidence for individualized treatment decisions.

18 Review Current issues in contraception. 2013

Marnach, Mary L / Long, Margaret E / Casey, Petra M. ·Division of Gynecology, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN 55905, USA. marnach.mary@mayo.edu ·Mayo Clin Proc · Pubmed #23489454.

ABSTRACT: Contraceptive management in women should take into account patient lifestyle and coexisting medical issues as well as method safety, efficacy, and noncontraceptive benefits. This review focuses on common and timely issues related to contraception encountered in clinical practice, including migraine headaches and associated risk of ischemic stroke, the use of combined hormonal contraception along with citalopram and escitalopram, contraceptive efficacy and safety in the setting of obesity, contraceptives for treatment of menorrhagia, the association of intrauterine contraception and decreased risk of cervical cancer, and the association of venous thromboembolism and combined hormonal contraception. Recent trends supporting the use of long-acting reversible contraception are also reviewed.

19 Review Human studies in the pathophysiology of migraine: genetics and functional neuroimaging. 2013

Cutrer, F Michael / Smith, Jonathan H. ·Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA. ·Headache · Pubmed #23278104.

ABSTRACT: The expansion of technologies available for the study of migraine pathophysiology has evolved greatly over the last 15 years. Two areas of rapid progress are investigations focusing on the genetics of migraine and others utilizing novel functional neuroimaging techniques. Genetic studies are increasingly focusing on sporadic migraine and the utilization of unbiased searches of the human genome to identify novel variants associated with disease susceptibility. At the same time, neuroimaging studies have provided novel insights into the altered neuronal and network dynamics of the migrainous brain. These 2 parallel approaches provide complementary insights into the complexity and heterogeneity of migraine.

20 Review Chronic subjective dizziness. 2012

Staab, Jeffrey P. ·Mayo Clinic, Department of Psychiatry and Psychology, 200 1st Street SW, Rochester, MN 55905, USA. staab.jeffrey@mayo.edu ·Continuum (Minneap Minn) · Pubmed #23042063.

ABSTRACT: PURPOSE OF REVIEW: In 1986, the German neurologists Thomas Brandt and Marianne Dieterich described a syndrome of phobic postural vertigo (PPV) based on clinical observations of patients with nonvertiginous dizziness that could not be explained by then-known neuro-otologic disorders. Subsequent research by an American team led by Jeffrey Staab and Michael Ruckenstein confirmed the core physical symptoms of PPV, clarified its relationship to behavioral factors, and streamlined its definition, calling the syndrome chronic subjective dizziness (CSD). This article reviews the 26-year history of PPV and CSD and places it within the context of current neurologic practice. RECENT FINDINGS: Recent investigations in Europe, the United States, Israel, and Japan have validated the primary symptoms of CSD; identified its provoking factors and precipitants; elucidated its long-term clinical course, differential diagnosis, and common comorbidities; developed successful treatment strategies with serotonergic antidepressants, vestibular habituation, and possibly cognitive-behavioral therapy; and raised new hypotheses about pathophysiologic processes that initiate and maintain the disorder. In tertiary neuro-otology centers where it is recognized, CSD is the second most common diagnosis among patients presenting with vestibular symptoms. SUMMARY: A quarter century of research has established CSD as a common clinical entity in neurologic and otorhinolaryngologic practice. Its identification and treatment offer relief to many patients previously thought to have enigmatic and unmanageable cases of persistent dizziness. Internationally sanctioned diagnostic criteria for CSD are under development for the first edition of the International Classification of Vestibular Disorders, scheduled for publication in early 2013.

21 Review Hormonal contraception and migraine: clinical considerations. 2012

Faubion, Stephanie S / Casey, Petra M / Shuster, Lynne T. ·Division of Preventive, Occupational, and Aerospace Medicine, Mayo Clinic, Women's Health Clinic, 200 First Street Southwest, Rochester, MN 55905, USA. faubion.stephanie@mayo.edu ·Curr Pain Headache Rep · Pubmed #22648178.

ABSTRACT: Migraine is highly prevalent in women, particularly in the reproductive years when contraception may be needed. Preventive strategies are known to be underutilized for migraine. Women of reproductive age may not only benefit from the use of hormonal contraceptives for contraception, but also for the purpose of reducing the burden of menstrual-related migraine. Although migraine is associated with an increased risk of stroke, the use of low-dose hormonal contraceptives in otherwise healthy women does not appear to confer additional risk.

22 Review The melanopsin system: Phototransduction, projections, functions, and clinical implications. 2011

Benarroch, Eduardo E. ·Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA. benarroch.eduardo@mayo.edu ·Neurology · Pubmed #21502603.

ABSTRACT: -- No abstract --

23 Review Nutraceuticals and headache: the biological basis. 2011

Taylor, Frederick R. ·From the Park Nicollet Headache Center, Park Nicollet Health Services, Minneapolis, MN, USA. ·Headache · Pubmed #21352223.

ABSTRACT: Nutrition must affect the structure and functioning of the brain. Since the brain has very high metabolic activity, what we consume throughout the day is likely to dramatically influence both its structure and moment to moment function. It follows that nutritional approaches to all neurological disorders are being researched and entering medical practice, while nutraceutical use is a mainstay of public habits. This review discusses the biological basis for non-conventional or non-mainstream approaches to the treatment of migraine. This requires at least limited discussion of current migraine pathophysiologic theory. How nutrients and other chemicals and approaches are mechanistically involved within migraine pathways is the focus of this article. The nutraceuticals reviewed in detail are: magnesium, riboflavin, coenzyme Q10, petasites, and feverfew with additional comments on marijuana and oxygen/hyperbaric oxygen. This article reviews the science when known related to the potential genetic susceptibility and sensitivity to these treatments. As we know, the basic science in this field is very preliminary, so whether to combine approaches and presumably mechanisms or use them alone or with or without conventional therapies is far from clear. Nonetheless, as more patients and providers participate in patient-centered approaches to care, knowledge of the science underpinning nutritional, nutraceutical, and complementary approaches to treatment for migraine will certainly benefit this interaction.

24 Review Na+, K+-ATPase: functions in the nervous system and involvement in neurologic disease. 2011

Benarroch, Eduardo E. ·Department of Neurology, Mayo Clinic, 200 First Street SW, West 8A Mayo Bldg., Rochester, MN 55905, USA. benarroch.eduardo@mayo.edu ·Neurology · Pubmed #21242497.

ABSTRACT: -- No abstract --

25 Review Management of migraine headache in the emergency department. 2010

Robertson, Carrie E / Black, David F / Swanson, Jerry W. ·Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. ·Semin Neurol · Pubmed #20352590.

ABSTRACT: Headache is one of the more common reasons for adults to visit an emergency department. Most of these visits are for primary headache disorders, most commonly migraine headache. The authors discuss management options for patients presenting to the emergency department with prolonged, severe, or refractory migraine headaches. Particular attention is given to parenteral treatments and protocols that would not be options as an outpatient. The epidemiology, investigation, and outpatient management of migraine headache are discussed in other articles in this issue.